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Dr Kavous Hakim-Meibodi (Bad Oeynhausen, Germany).
Thank you, Dr Sabashnikov, for presenting your work pushing
the limits on the treatment of very ill patients with failing left ven-
tricular function. Since the first implantation of the device in 2008,
it has been on and off the market several times for technical prob-
lems. Finally, the CE mark was achieved in 2012.
In your current study, you have achieved some remarkable re-
sults using this device for very ill patients, INTERMACS class I
to III. I congratulate you on these results. On the other hand,
perhaps some of the reported results need some second thought.
You reported the variety of patients in INTERMACS class I to
III. What were the criteria to use this device for this kind of patient
instead of the full LVAD?
Dr Sabashnikov.At that time, we didn’t have any data on using
this device in patients with INTERMACS classes higher than IV
because the device was actually approved for less sick patients
without inotropic dependency.
However, we thought some patients would benefit from this de-
vice, and we implanted it preferably in patients with low body
mass index and with deterioration that had started recently with
still available cardiac output. Because our idea was that despite
low flow of a maximum of 4.25 liters, this support was being added
to the remaining cardiac output of patients. Cardiac output was
enough for most of them. That was the main idea why we started
using the device in inotropic-dependent patients.
Our results showed that only 16% of patients had to be upgraded.
As Imentioned, the risk of upgrade is lower because it’s thefirst ster-
notomy, and it should not be considered a redo procedure.
Dr Hakim-Meibodi. Four of 12 patients had pump thrombosis.
In my opinion, this is a high rate. I guess it’s device related. How
did you proceed? Did you just exchange the pump or also the
inflow part, which is intrathoracal?
Dr Sabashnikov. Device thrombosis is the most important part
of this story because a high number of complications occurred.
However, the device is new, and I have to mention that other de-
vices had similar problems in the beginning, and after several
manufacturer changes, the quality of the devices improved.
So now we are in the phase when this device is being refined.
Some manufacturer changes are being performed, and we hope
that next year we will have a completely new version of this: a par-
tial-support device with significantly lower risk of thrombosis. In
all cases, we treat thrombosis by exchanging the device because
it’s a short and easy procedure. In all cases, we leave the inflow
cannula in situ. However, we left the clamp open for a couple of
seconds to be sure that the cannula is free of thrombi.
Dr Hakim-Meibodi. Don’t you think this small inflow cannula
far from the pump is one of the reasons for the thrombosis, the sys-
tematic problem for this device?
Dr Sabashnikov. No. According to our investigations, most
thrombotic structures occurred in the pump itself, so we were
not really worried about the cannula.
Dr Hakim-Meibodi. Don’t you think this high rate of throm-
bosis is particularly dangerous in this pump-dependent group of
patients? So this is something that is well tolerated if the patient
has enough rest output, but if he’s depending on the pump, it could
be a severe problem.1122 The Journal of Thoracic and Cardiovascular SurDr Sabashnikov. Sure. We were lucky that all pump thrombo-
ses occurred when patients were still in the hospital, and patients
theoretically might have been put on inotropic support, but we
managed to do it without. Nevertheless, that’s a good point that
inotropic-dependent patients might deteriorate because of low car-
diac output, at home if they develop pump thrombosis and still
have not recovered at least a little bit. However, it can happen
with any device.
DrHakim-Meibodi.You reported 1 patient who already had an
LVAD. What were the criteria to implant this pump in this patient
and what did you do to the assist device? Did you explant it?
Dr Sabashnikov. It was a young patient who had undergone im-
plantation with a full-flow assist device via median sternotomy a
long time ago, and he underwent explantation of the assist device
because of myocardial recovery later and was free of heart failure
symptoms for a long period of time. Once he developed heart
failure symptoms again and was deteriorating, we decided to go
for a less-invasive procedure because of the previous full
sternotomy.
Dr Nader Moazami (Cleveland, Ohio). The concept of partial
support is interesting, specifically in the very sick patients who
have received this device. I think we always use the yardstick of
survival as a measure of success.
What I didn’t see in your presentation is how do the hemody-
namics of these patients improve? What was the functional status
of these patients? Were any discharged or were they in the hospital
all the time?
The reason I say that is because, as you know, this technology is
now off the shelf because of multiple problems. Thrombosis is just
one of the problems. There are many other problems, and there are
other pumps that can now be implanted through minithoracoto-
mies that can provide full support. So we should be careful, specif-
ically because of the bad experience with left atrial cannulation in
general. What was the functional status of these patients?
Dr Sabashnikov. One patient died. All other patients under-
went transplantation or are on ongoing support, and all of them
were discharged.
Regarding your good points, we are now in the beginning area
of this partial support and already have seen results. Thrombosis
and other complications that occurred during LVAD support in
the beginning are normal signs, and that’s why the device is tempo-
rarily suspended. But our general idea is not related to this partic-
ular device but to the partial support in general. So people can use
this information after development of new partial-flow devices,
and particularly after the Synergy device has been upgraded to a
better model and is available on the market again.
DrOztekin Oto (Izmir, Turkey). Youmentioned that you had no
RVF at all, although you are partially supporting and these are very
ill patients. What is the secret then, and what are your RVF
criteria?
Dr Sabashnikov.We are not sure, but it might be related to the
low transfusion rate because it’s a less invasive procedure without
sternotomy. Also, it’s a short implantation with lower trauma. But
it’s still unclear, because it’s a very new area.
Dr Jose Pomar (Barcelona, Spain). Just to tell you, the next
time, please remember that not everybody knows what the Synergy
pump is, and it would be nice to have a picture at the beginning.gery c September 2014
